ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Samsung BioLogics claims contract biopharma crown

Completion of third plant doubles production capacity

Samsung Biologics' third plant in Incheon, South Korea, is capable of producing 180,000 liters of products a year.

SEOUL -- Samsung BioLogics has become the world's largest contract manufacturer of biopharmaceuticals by output capacity, the company said, with the recent completion of its third plant.

The company invested 850 billion won ($759 million) to build the new plant, located in Incheon on the outskirts of Seoul, doubling its total production capacity to 360,000 liters a year and putting it ahead of Switzerland's Lonza and Germany's Boehringer Ingelheim.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more